Next Article in Journal
Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)
Previous Article in Journal
“To Do or Not to Do, That Is the Question”, Surgery and Pregnancy
 
 
Review

Article Versions Notes

J. Clin. Med. 2022, 11(17), 5096; https://doi.org/10.3390/jcm11175096
Action Date Notes Link
article pdf uploaded. 30 August 2022 13:55 CEST Version of Record https://www.mdpi.com/2077-0383/11/17/5096/pdf-vor
article xml file uploaded 1 September 2022 07:41 CEST Original file -
article xml uploaded. 1 September 2022 07:41 CEST Update https://www.mdpi.com/2077-0383/11/17/5096/xml
article pdf uploaded. 1 September 2022 07:41 CEST Updated version of record https://www.mdpi.com/2077-0383/11/17/5096/pdf
article html file updated 1 September 2022 07:42 CEST Original file -
article html file updated 28 February 2023 11:29 CET Update https://www.mdpi.com/2077-0383/11/17/5096/html
Back to TopTop